Macugen Observational Study

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

NCT00549055 ·Status: COMPLETED

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

NCT00460408 ·Status: COMPLETED

Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

NCT00845273 ·Status: COMPLETED

Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

NCT00087763 ·Status: COMPLETED ·Phase: PHASE2

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)

NCT00446381 ·Status: COMPLETED ·Phase: NA

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

NCT03869684 ·Status: TERMINATED ·Phase: PHASE2

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572 ·Status: COMPLETED ·Phase: PHASE4

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

NCT05390840 ·Status: RECRUITING ·Phase: PHASE2

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

NCT00354445 ·Status: UNKNOWN ·Phase: PHASE4

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

NCT01678872 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

NCT03128463 ·Status: UNKNOWN

Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD

NCT01213667 ·Status: UNKNOWN ·Phase: PHASE4

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

NCT00090532 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes

NCT04776031 ·Status: COMPLETED ·Phase: NA

Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

NCT00324116 ·Status: COMPLETED ·Phase: PHASE4

Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion

NCT04836143 ·Status: COMPLETED

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

NCT01624636 ·Status: TERMINATED ·Phase: PHASE2

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107 ·Status: COMPLETED ·Phase: PHASE4

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

NCT04270669 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

NCT01601483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950 ·Status: COMPLETED ·Phase: PHASE2

Monocentric Retrospective Observational Study on Patients With Macular Degeneration

NCT02089503 ·Status: UNKNOWN

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

NCT04884399 ·Status: COMPLETED ·Phase: PHASE1

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

NCT06817343 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

NCT03699618 ·Status: TERMINATED